Advertisement
Screener

SCHOLAR ROCK HOLDING CORPORATION (SRRK) Graph

SRRK Revenue Flow

Filed revenue amounts for 2026-01-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue (m); Revenue including tax (m); Research and development $58.23M; Operating expenses $108.90M.
  • 2026-03-31: Revenue $0.00; Revenue including tax (m); Research and development $51.81M; Operating expenses $102.02M.
  • 2025-12-31: Revenue $0.00*; Revenue including tax (m); Research and development $46.88M*; Operating expenses $91.90M*.
  • 2025-09-30: Revenue (m); Revenue including tax (m); Research and development $50.49M; Operating expenses $103.55M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

SRRK revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$210.92MOperating income-$210.92MOther income, net-$1.36MResearch & development$110.05MNet income-$215.41M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesNet income
2026-06-30(m)(m)$58.23M$108.90M-$109.90M
2026-03-31$0.00(m)$51.81M$102.02M-$105.51M
2025-12-31$0.00*(m)$46.88M*$91.90M*-$91.03M*
2025-09-30(m)(m)$50.49M$103.55M-$102.22M
2025-06-30(m)(m)$62.40M$112.11M-$110.03M
2025-03-31(m)(m)$48.68M$77.09M-$74.72M
2024-09-30(m)(m)$48.72M$64.78M-$64.48M
2024-06-30(m)(m)$42.37M$59.50M-$58.51M
2024-03-31(m)(m)$43.09M$58.42M-$56.85M
2023-09-30(m)(m)$30.34M$43.67M-$42.36M
2023-06-30(m)(m)$26.87M$39.08M-$37.92M
2023-03-31(m)(m)$29.73M$40.51M-$39.38M
2022-09-30(m)(m)$33.39M$43.86M-$43.30M
2022-06-30(m)(m)$32.07M$43.15M-$44.00M
2022-03-31$33.19M(m)$29.37M$40.13M-$7.95M
2021-09-30$5.46M(m)$31.27M$42.54M-$37.51M
2021-06-30$4.59M(m)$25.60M$34.87M-$30.71M
2021-03-31$4.71M(m)$22.55M$31.91M-$27.67M
2020-09-30$3.04M(m)$18.38M$26.66M-$23.56M
2020-06-30$3.90M(m)$17.00M$23.36M-$19.28M
2020-03-31$5.03M(m)$16.90M$22.72M-$17.07M
2019-09-30$4.77M(m)$15.70M$21.88M-$16.15M
2019-06-30$5.04M(m)$13.71M$18.43M-$12.53M
2019-03-31$3.11M$3.11M$10.74M$14.81M-$10.76M
2018-12-31$0.00*(m)(m)(m)(m)
2018-09-30$0.00(m)$8.06M$11.23M-$10.76M
2018-06-30$0.00(m)$11.42M$14.88M-$14.71M
2018-03-31(m)(m)$6.70M$9.02M-$8.89M
2017-09-30$0.00(m)$4.78M$5.94M-$5.93M
2017-06-30$0.00(m)$4.71M$5.89M-$5.88M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30$0.00$110.05M$210.92M-$215.41M
2025-06-30$0.00$111.08M$189.20M-$184.75M
2024-06-30(m)$85.47M$117.92M-$115.36M
2023-06-30(m)$56.60M$79.59M-$77.30M
2022-06-30$33.19M$61.44M$83.27M-$51.95M
2021-06-30$9.30M$48.15M$66.78M-$58.38M
2020-06-30$8.93M$33.90M$46.09M-$36.35M
2019-06-30$8.14M$24.45M$33.23M-$23.28M
2018-06-30$0.00$18.13M$23.90M-$23.60M
2017-06-30$0.00$8.28M$10.63M-$10.61M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30$0.00$161.56M$292.75M-$286.97M
2024-09-30(m)$134.19M$182.70M-$179.84M
2023-09-30(m)$86.94M$123.26M-$119.66M
2022-09-30$33.19M$94.83M$127.14M-$95.25M
2021-09-30$14.77M$79.42M$109.32M-$95.89M
2020-09-30$11.97M$52.28M$72.74M-$59.91M
2019-09-30$12.92M$40.15M$55.11M-$39.43M
2018-09-30$0.00$26.18M$35.13M-$34.36M
2017-09-30$0.00$13.06M$16.57M-$16.54M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-12-31$0.00$208.44M$384.64M-$378.00M
2024-12-31(m)$184.55M$252.05M-$246.00M
2023-12-31(m)$121.90M$171.29M-$166.00M
2022-12-31$33.19M$124.44M$167.56M-$134.50M
2021-12-31$18.82M$108.47M$148.74M-$131.80M
2020-12-31$15.40M$74.06M$102.28M-$86.48M
2019-12-31$20.49M$54.22M$75.03M-$51.00M
2018-12-31$0.00$36.31M$50.69M-$49.33M
2017-12-31(m)$19.94M$25.03M-$25.00M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CG Oncology, Inc. (CGON)United States$6.095B-27.95
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29